Anne Claire B van Orten-Luiten, Elske M Brouwer-Brolsma, André Janse, Renger F Witkamp
{"title":"A drug-based model to predict hyponatremia in outpatients of a geriatric clinic.","authors":"Anne Claire B van Orten-Luiten, Elske M Brouwer-Brolsma, André Janse, Renger F Witkamp","doi":"10.1007/s00228-025-03890-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Chronic hyponatremia in older people is associated with adverse outcomes including gait disturbances, falls, osteoporosis, fractures, cognitive impairment, and cardiovascular disease. Diagnosis in outpatient settings is challenging due to the non-specific nature of its symptoms. While hyponatremia is well-studied in hospitalized patients, little research has focused on outpatient settings. This study aimed to develop a drug-based model to non-invasively predict hyponatremia in older adults attending a geriatric outpatient clinic.</p><p><strong>Methods: </strong>Cross-sectional data from 2181 outpatients aged ≥ 55 were analysed using logistic regression. Polypharmacy, 27 specific drug groups, sex, age, and BMI were considered as potential risk factors. Predictors were selected using stepwise backward logistic regression for the complex model and LASSO regression for the simple model. Internal validation was performed through bootstrapping, and model performance was evaluated by constructing a receiver operating characteristic (ROC) curve.</p><p><strong>Results: </strong>The prevalence of hyponatremia was 10.5%, with higher occurrence in women. The complex model identified predictors including sex, age, BMI, polypharmacy, and 11 drug groups, achieving an area under the curve (AUC) of 0.75, [95% CI 0.72-0.79], indicating a reasonably good ability to distinguish between hypo- and normonatremia. The simple model, including only polypharmacy, had limited predictive performance (AUC = 0.64 [95% CI 0.60-0.68]).</p><p><strong>Conclusion: </strong>The complex, drug-based model predicts hyponatremia risk in outpatients of a geriatric clinic. Timely recognition may prevent inappropriate treatments for undiagnosed cases and associated harms. The model merits further development for clinical use.</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":"1507-1515"},"PeriodicalIF":2.7000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12443923/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00228-025-03890-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/1 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Chronic hyponatremia in older people is associated with adverse outcomes including gait disturbances, falls, osteoporosis, fractures, cognitive impairment, and cardiovascular disease. Diagnosis in outpatient settings is challenging due to the non-specific nature of its symptoms. While hyponatremia is well-studied in hospitalized patients, little research has focused on outpatient settings. This study aimed to develop a drug-based model to non-invasively predict hyponatremia in older adults attending a geriatric outpatient clinic.
Methods: Cross-sectional data from 2181 outpatients aged ≥ 55 were analysed using logistic regression. Polypharmacy, 27 specific drug groups, sex, age, and BMI were considered as potential risk factors. Predictors were selected using stepwise backward logistic regression for the complex model and LASSO regression for the simple model. Internal validation was performed through bootstrapping, and model performance was evaluated by constructing a receiver operating characteristic (ROC) curve.
Results: The prevalence of hyponatremia was 10.5%, with higher occurrence in women. The complex model identified predictors including sex, age, BMI, polypharmacy, and 11 drug groups, achieving an area under the curve (AUC) of 0.75, [95% CI 0.72-0.79], indicating a reasonably good ability to distinguish between hypo- and normonatremia. The simple model, including only polypharmacy, had limited predictive performance (AUC = 0.64 [95% CI 0.60-0.68]).
Conclusion: The complex, drug-based model predicts hyponatremia risk in outpatients of a geriatric clinic. Timely recognition may prevent inappropriate treatments for undiagnosed cases and associated harms. The model merits further development for clinical use.
目的:老年人慢性低钠血症与不良后果相关,包括步态障碍、跌倒、骨质疏松、骨折、认知障碍和心血管疾病。由于其症状的非特异性,门诊诊断具有挑战性。虽然低钠血症在住院患者中得到了很好的研究,但很少有研究关注门诊患者。本研究旨在开发一种基于药物的无创模型来预测老年门诊患者的低钠血症。方法:采用logistic回归分析2181例年龄≥55岁门诊患者的横断面资料。多药、27个特定药物组、性别、年龄和BMI被认为是潜在的危险因素。对复杂模型采用逐步后向逻辑回归,对简单模型采用LASSO回归。通过自举进行内部验证,并通过构建受试者工作特征(ROC)曲线来评估模型的性能。结果:低钠血症的患病率为10.5%,女性发病率较高。该复杂模型确定的预测因子包括性别、年龄、BMI、多种药物和11种药物组,曲线下面积(AUC)为0.75,[95% CI 0.72-0.79],表明区分低钠和正常钠的能力相当好。简单模型,仅包括多药,预测效果有限(AUC = 0.64 [95% CI 0.60-0.68])。结论:复杂的、基于药物的模型预测老年门诊患者低钠血症的风险。及时识别可以防止对未确诊病例的不当治疗和相关危害。该模型值得进一步开发用于临床应用。
期刊介绍:
The European Journal of Clinical Pharmacology publishes original papers on all aspects of clinical pharmacology and drug therapy in humans. Manuscripts are welcomed on the following topics: therapeutic trials, pharmacokinetics/pharmacodynamics, pharmacogenetics, drug metabolism, adverse drug reactions, drug interactions, all aspects of drug development, development relating to teaching in clinical pharmacology, pharmacoepidemiology, and matters relating to the rational prescribing and safe use of drugs. Methodological contributions relevant to these topics are also welcomed.
Data from animal experiments are accepted only in the context of original data in man reported in the same paper. EJCP will only consider manuscripts describing the frequency of allelic variants in different populations if this information is linked to functional data or new interesting variants. Highly relevant differences in frequency with a major impact in drug therapy for the respective population may be submitted as a letter to the editor.
Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves
-a compound that is interesting and new in some basic or fundamental way, or
-methods that are original in some basic sense, or
-a highly unexpected outcome, or
-conclusions that are scientifically novel in some basic or fundamental sense.